1. Clinical & Scientific Overview
Melphalan (TIP-MED-000551, Reference Code [ONC-02]) is classified under
Oncology & Antineoplastic Medicines as a Alkylating Agent • Phenylalanine Nitrogen Mustard Bifunctional Alkylating Agent.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Alkeran (Aspen / GSK Reference), Alphalan (Natco Pharma), Megval (Emcure Pharmaceuticals)
Film-Coated Tablet: 2 mg, 5 mg; Lyophilised Powder for IV Conditioning: 50 mg vial
Oncology Specialisation & Cytotoxic Safety Protocol
Alkylating Agent
Antineoplastic Cytotoxic
Standard Regimen & Cycle Context: ASCT conditioning: 200 mg/m2 IV (reduced to 140 mg/m2 if CrCl <60 mL/min) followed by stem cell rescue 24–48 hours later.
Signature Dose-Limiting Toxicities & Organ Monitoring: Profound dose-limiting myeloablation, severe oral/gastrointestinal mucositis (mitigated by oral cryotherapy/ice chips for 30 minutes before, during, and after IV infusion), pulmonary fibrosis, and secondary MDS/AML.
Extravasation, Premedication & Safe Cytotoxic Handling: Reconstituted IV Melphalan hydrolyses rapidly in 0.9% NaCl (loses ~1% potency every 10 minutes); dilute to <=0.45 mg/mL in 0.9% NaCl and complete infusion within 60 minutes of reconstitution! Oral tablets must be taken on an empty stomach (food cuts bioavailability by 40%).
3. Mechanism of Action & Pharmacodynamics
Substitutes L-phenylalanine onto a bis(2-chloroethyl)amine group, entering tumour cells via L-type amino acid transporters (LAT1) and alkylating the N7 position of guanine to form interstrand and intrastrand DNA cross-links.
4. Therapeutic Indications & Evidence-Supported Uses
- High-dose conditioning (200 mg/m2 IV) prior to autologous stem cell transplantation (ASCT) in Multiple Myeloma
- Palliative oral therapy in transplant-ineligible myeloma
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): ASCT conditioning: 200 mg/m2 IV (reduced to 140 mg/m2 if CrCl <60 mL/min) followed by stem cell rescue 24–48 hours later.
Administration & Meal Timing: ASCT conditioning: 200 mg/m2 IV (reduced to 140 mg/m2 if CrCl <60 mL/min) followed by stem cell rescue 24–48 hours later.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Melphalan or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: Profound dose-limiting myeloablation, severe oral/gastrointestinal mucositis (mitigated by oral cryotherapy/ice chips for 30 minutes before, during, and after IV infusion), pulmonary fibrosis, and secondary MDS/AML.
8. Adverse Effects Profile
- Profound dose-limiting myeloablation, severe oral/gastrointestinal mucositis (mitigated by oral cryotherapy/ice chips for 30 minutes before, during, and after IV infusion), pulmonary fibrosis, and secondary MDS/AML.
- Profound dose-limiting myeloablation, severe oral/gastrointestinal mucositis (mitigated by oral cryotherapy/ice chips for 30 minutes before, during, and after IV infusion), pulmonary fibrosis, and secondary MDS/AML.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Profound dose-limiting myeloablation, severe oral/gastrointestinal mucositis (mitigated by oral cryotherapy/ice chips for 30 minutes before, during, and after IV infusion), pulmonary fibrosis, and secondary MDS/AML.
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Reconstituted IV Melphalan hydrolyses rapidly in 0.9% NaCl (loses ~1% potency every 10 minutes); dilute to <=0.45 mg/mL in 0.9% NaCl and complete infusion within 60 minutes of reconstitution! Oral tablets must be taken on an empty stomach (food cuts bioavailability by 40%).
Pharmacist Patient Counselling Points:
- Reconstituted IV Melphalan hydrolyses rapidly in 0.9% NaCl (loses ~1% potency every 10 minutes); dilute to <=0.45 mg/mL in 0.9% NaCl and complete infusion within 60 minutes of reconstitution! Oral tablets must be taken on an empty stomach (food cuts bioavailability by 40%).
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: Reconstituted IV Melphalan hydrolyses rapidly in 0.9% NaCl (loses ~1% potency every 10 minutes); dilute to <=0.45 mg/mL in 0.9% NaCl and complete infusion within 60 minutes of reconstitution! Oral tablets must be taken on an empty stomach (food cuts bioavailability by 40%).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [ONC-01] Ifosfamide — Alkylating Agent (Prodrug) • Oxazaphosphorine Nitrogen Mustard Al
- [ONC-03] Temozolomide — Alkylating / Methylating Agent • Imidazotetrazine Oral DNA Methyl
- [ONC-04] Cytarabine (Ara-C) — Antimetabolite (S-Phase Specific) • Pyrimidine Nucleoside Analogu
- [ONC-05] Gemcitabine Hydrochloride — Antimetabolite (Pyrimidine Analogue) • Deoxycytidine Fluorinated
